FDA Permanently Fills Four Key Leadership Roles — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump administration permanently filled four key FDA leadership roles on Tuesday, with three officials shifting from acting to permanent status in the same positions.
- Michael Davis, a psychiatrist, was named permanent director of the FDA's Center for Drug Evaluation and Research.
- Karim Mikhail, a former Merck official, was named permanent director of the Center for Biologics Evaluation and Research.
- Bret Koplow, an attorney at the FDA since 2011, will serve as permanent director of the Center for Tobacco Products.
- The permanent appointments follow Heidi Overton's nomination to lead the FDA late last month.
Why it matters: Three of the four appointees shift from acting to permanent status, locking in leadership at the centers that gatekeep drug approvals, biologics reviews, and tobacco product regulation in the U.S. The fourth role was not named in this excerpt, but the slate is now complete ahead of Overton's confirmation process to lead the agency.
Ask SkimNews
